Frances K. Wiseman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frances K. Wiseman has a total of 358 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth M. C. Fisher
Department of Neuromuscular Diseases, and UCL Queen Square Motor Neuron Disease Centre, UCL, Institute of Neurology, London, UK
32 shared publications - Victor L. J. Tybulewicz
The Francis Crick Institute, London, UK
21 shared publications Karen Cleverley
Affiliation Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, United Kingdom
13 shared publicationsPaige Mumford
UK Dementia Research Institute at UCL London UK
10 shared publications- Paige Mumford
UK Dementia Research Institute, University College London, London United Kingdom
9 shared publications - Clíona Farrell
UK Dementia Research Institute, University College London, London United Kingdom
6 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 632-634
New mouse models for Down syndrome Alzheimer's disease
In this issue Ishihara and colleagues report the development and characterization of new mouse models for Down syndrome Alzheimer's disease, the most commonly occurring genetic cause of dementia worldwide. These new models add to the growing portfolio of in vivo models of Down syndrome. In particular, the new Ts1Kei-APPswe/PS1 dE9 model may be highly useful for the study and identification of novel treatment targets for late onset myoclonic epilepsy of Down syndrome. This seizure disorder is a common comorbidity of Down syndrome Alzheimer's disease affecting around half of all people with the condition and is associated with particularly adverse clinical outcomes.
- 17 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 632-634
Open AccessNew mouse models for Down syndrome Alzheimer's disease
In this issue Ishihara and colleagues report the development and characterization of new mouse models for Down syndrome Alzheimer's disease, the most commonly occurring genetic cause of dementia worldwide. These new models add to the growing portfolio of in vivo models of Down syndrome. In particular, the new Ts1Kei-APPswe/PS1 dE9 model may be highly useful for the study and identification of novel treatment targets for late onset myoclonic epilepsy of Down syndrome. This seizure disorder is a common comorbidity of Down syndrome Alzheimer's disease affecting around half of all people with the condition and is associated with particularly adverse clinical outcomes.
- Open Access
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71619
Using Machine Learning to Automate the Analysis of an Olfactory Habituation‐Dishabituation Task in Mice
Introduction: Improving the efficiency and accuracy of annotation and extraction of performance data from mouse behavioral tasks will improve both the throughput and scientific value of preclinical research. Methods: Here, we present and validate an automated pipeline for the annotation and quantification of performance in a mouse olfactory habituation‐dishabituation task, using a single side‐view camera, resulting in occluded body parts. We created a pipeline for task analysis, combining DeepLabCut (DLC) for pose‐estimation and SimBA, for behavioral classification to automatically quantify odor interaction (sniffing time) in a three‐odor (water, familiar mouse social odor, novel mouse social odor) variant of the task. We used a subset of previously published, fully manually annotated datasets to train the models and unseen videos from the same study to validate the utility of our machine learning (ML) pipeline. Results and Conclusion: Our analysis pipeline estimated behavioral performance in the task with high accuracy, and the data produces similar technical and biological results to manual methods when analyzed by linear mixed modeling. Thus, we validated the utility of our customized pipeline for the automated scoring of this mouse sensory task, and we discuss its strengths and limitations.
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71619
Open AccessUsing Machine Learning to Automate the Analysis of an Olfactory Habituation‐Dishabituation Task in Mice
Introduction: Improving the efficiency and accuracy of annotation and extraction of performance data from mouse behavioral tasks will improve both the throughput and scientific value of preclinical research. Methods: Here, we present and validate an automated pipeline for the annotation and quantification of performance in a mouse olfactory habituation‐dishabituation task, using a single side‐view camera, resulting in occluded body parts. We created a pipeline for task analysis, combining DeepLabCut (DLC) for pose‐estimation and SimBA, for behavioral classification to automatically quantify odor interaction (sniffing time) in a three‐odor (water, familiar mouse social odor, novel mouse social odor) variant of the task. We used a subset of previously published, fully manually annotated datasets to train the models and unseen videos from the same study to validate the utility of our machine learning (ML) pipeline. Results and Conclusion: Our analysis pipeline estimated behavioral performance in the task with high accuracy, and the data produces similar technical and biological results to manual methods when analyzed by linear mixed modeling. Thus, we validated the utility of our customized pipeline for the automated scoring of this mouse sensory task, and we discuss its strengths and limitations.
- Open Access
- 16 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104633
Considerations for the selection and phenotyping of mouse models for the study of Alzheimer’s disease
- 16 June 2026
- Published by Elsevier in STAR Protocols
- Vol. 7 (3) , 104633
Open AccessConsiderations for the selection and phenotyping of mouse models for the study of Alzheimer’s disease
- Open Access
- 6 June 2026
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 28 (1)
Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society
Down syndrome (DS), or trisomy 21 (T21), represents the most common genetic cause of intellectual disability worldwide and is associated with a wide range of medical, developmental, and neurodegenerative conditions, including a universal predisposition to early-onset Alzheimer’s disease (AD). Since its establishment in 2014, the Trisomy 21 Research Society (T21RS) has provided a global forum for advancing DS research across disciplines and promoting translational efforts to improve health and quality of life. Every two years, T21RS hosts an international scientific meeting that brings together researchers, clinicians, self-advocates, families, and industry stakeholders. In 2024, the 5th T21RS International Conference was held in Rome, Italy, from June 5 to 8, under the theme “Promoting Research Excellence in Down Syndrome.” The meeting brought together about 500 scientists from 26 countries across five continents, and more than 900 attendees overall, including families and caregivers. The scientific program featured 5 keynote lectures, 2 satellite meetings, 17 symposia, 7 nano symposia, 2 workshops, and 1 industry-focused session, totaling more than 150 oral presentations. More than 230 abstracts were presented as posters. The conference covered research across the lifespan of individuals with DS, spanning genomic and epigenetic regulation, molecular and cellular mechanisms, preclinical and experimental models, cognition and behavior, neurodevelopment, aging and neurodegeneration, co-occurring medical conditions, and therapeutic interventions. Dedicated sessions focused on capacity-building in DS research and societal engagement were established. Significantly, T21RS promoted inclusivity by supporting 60 young investigator fellowships, providing childcare awards, and organizing a two-day program for families and caregivers in collaboration with Italian DS associations. This proceeding summarizes the main scientific highlights of the 5th T21RS International Conference, reflecting the latest advances in DS biology, clinical research, biomarker development, and therapeutic innovation.
- 6 June 2026
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 28 (1)
Open AccessPromoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society
Down syndrome (DS), or trisomy 21 (T21), represents the most common genetic cause of intellectual disability worldwide and is associated with a wide range of medical, developmental, and neurodegenerative conditions, including a universal predisposition to early-onset Alzheimer’s disease (AD). Since its establishment in 2014, the Trisomy 21 Research Society (T21RS) has provided a global forum for advancing DS research across disciplines and promoting translational efforts to improve health and quality of life. Every two years, T21RS hosts an international scientific meeting that brings together researchers, clinicians, self-advocates, families, and industry stakeholders. In 2024, the 5th T21RS International Conference was held in Rome, Italy, from June 5 to 8, under the theme “Promoting Research Excellence in Down Syndrome.” The meeting brought together about 500 scientists from 26 countries across five continents, and more than 900 attendees overall, including families and caregivers. The scientific program featured 5 keynote lectures, 2 satellite meetings, 17 symposia, 7 nano symposia, 2 workshops, and 1 industry-focused session, totaling more than 150 oral presentations. More than 230 abstracts were presented as posters. The conference covered research across the lifespan of individuals with DS, spanning genomic and epigenetic regulation, molecular and cellular mechanisms, preclinical and experimental models, cognition and behavior, neurodevelopment, aging and neurodegeneration, co-occurring medical conditions, and therapeutic interventions. Dedicated sessions focused on capacity-building in DS research and societal engagement were established. Significantly, T21RS promoted inclusivity by supporting 60 young investigator fellowships, providing childcare awards, and organizing a two-day program for families and caregivers in collaboration with Italian DS associations. This proceeding summarizes the main scientific highlights of the 5th T21RS International Conference, reflecting the latest advances in DS biology, clinical research, biomarker development, and therapeutic innovation.
- Open Access
- 21 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71498
Age‐related behavioral and molecular landmarks in new mouse models for studying Alzheimer's disease in Down syndrome
INTRODUCTION: Down syndrome (DS) is the leading genetic cause of intellectual disability and Alzheimer's disease (AD), with over 90% of individuals developing AD‐related dementia (DSAD). The triplication of the APP gene on chromosome 21 drives early amyloid‐β (Aβ) accumulation, but other Hsa21 genes also contribute to pathology. Current DSAD models are limited by species‐specific Aβ differences. METHODS: We developed and characterized two novel DSAD mouse models with partial humanization of Aβ. RESULTS: These models exhibit early AD features: cognitive deficits, hyperactivity, altered novelty and risk responses, tau hyperphosphorylation, and endolysosomal dysfunction. Amyloid precursor protein (APP) processing shifts toward β‐secretase, increasing CTF‐β and altering Aβ dynamics. Aβ humanization modulates behavior, improving specific cognitive tasks but enhancing anxiety traits. Myelinosome formation and impaired autophagic flux further align these models with human AD pathology. DISCUSSION: They offer valuable tools to investigate early DSAD mechanisms and therapeutic strategies, pending development of a fully humanized trisomic model.
- 21 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71498
Open AccessAge‐related behavioral and molecular landmarks in new mouse models for studying Alzheimer's disease in Down syndrome
INTRODUCTION: Down syndrome (DS) is the leading genetic cause of intellectual disability and Alzheimer's disease (AD), with over 90% of individuals developing AD‐related dementia (DSAD). The triplication of the APP gene on chromosome 21 drives early amyloid‐β (Aβ) accumulation, but other Hsa21 genes also contribute to pathology. Current DSAD models are limited by species‐specific Aβ differences. METHODS: We developed and characterized two novel DSAD mouse models with partial humanization of Aβ. RESULTS: These models exhibit early AD features: cognitive deficits, hyperactivity, altered novelty and risk responses, tau hyperphosphorylation, and endolysosomal dysfunction. Amyloid precursor protein (APP) processing shifts toward β‐secretase, increasing CTF‐β and altering Aβ dynamics. Aβ humanization modulates behavior, improving specific cognitive tasks but enhancing anxiety traits. Myelinosome formation and impaired autophagic flux further align these models with human AD pathology. DISCUSSION: They offer valuable tools to investigate early DSAD mechanisms and therapeutic strategies, pending development of a fully humanized trisomic model.
- Open Access
- 27 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71404
Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease
INTRODUCTION: The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome. METHODS: This narrative review considers the ethical and biological factors relating to the administration of anti–amyloid‐β monoclonal antibody therapies to persons who have Down syndrome. Literature was selected based on relevance. RESULTS: Here, we discuss the current understanding of Down syndrome Alzheimer's disease, and how this informs potential benefits and risks of treatment with anti–amyloid‐β monoclonal antibodies. DISCUSSION: The blood–brain barrier and immune system differ in persons with Down syndrome, and cerebral amyloid angiopathy is elevated compared to late‐onset Alzheimer's disease. Thus, side‐effect risks from anti–amyloid‐β monoclonal antibodies are likely to be elevated. Further research is needed to facilitate the treatment of persons with Down syndrome with these new therapies.
- 27 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71404
Open AccessUse of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease
INTRODUCTION: The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome. METHODS: This narrative review considers the ethical and biological factors relating to the administration of anti–amyloid‐β monoclonal antibody therapies to persons who have Down syndrome. Literature was selected based on relevance. RESULTS: Here, we discuss the current understanding of Down syndrome Alzheimer's disease, and how this informs potential benefits and risks of treatment with anti–amyloid‐β monoclonal antibodies. DISCUSSION: The blood–brain barrier and immune system differ in persons with Down syndrome, and cerebral amyloid angiopathy is elevated compared to late‐onset Alzheimer's disease. Thus, side‐effect risks from anti–amyloid‐β monoclonal antibodies are likely to be elevated. Further research is needed to facilitate the treatment of persons with Down syndrome with these new therapies.
- Open Access
Using machine learning to automate the analysis of an olfactory habituation-dishabituation task in mice
Introduction: Improving the efficiency and accuracy of annotation and extraction of performance data from mouse behavioural tasks will improve both the throughput and scientific value of preclinical research. Methods: Here, we present and validate an automated pipeline for the annotation and quantification of performance in a mouse olfactory habituation-dishabituation task, using a single side-view camera, resulting in occluded body parts. We created a pipeline for task analysis, combining DeepLabCut, for pose-estimation, and SimBA, for behavioural classification to automatically quantify odour interaction (sniffing time) in a three-odour (water, familiar mouse social odour, novel mouse social odour) variant of the task. We used a subset of previously published, fully manually annotated datasets to train the models and unseen videos from the same study to validate the utility of our machine learning pipeline. Results and conclusion: Our analysis pipeline estimated behavioural performance in the task with high accuracy, and the data produces similar technical and biological results to manual methods when analysed by linear mixed modelling. Thus, we validated the utility of our new pipeline for the automated scoring of this mouse sensory task.
Open AccessUsing machine learning to automate the analysis of an olfactory habituation-dishabituation task in mice
Introduction: Improving the efficiency and accuracy of annotation and extraction of performance data from mouse behavioural tasks will improve both the throughput and scientific value of preclinical research. Methods: Here, we present and validate an automated pipeline for the annotation and quantification of performance in a mouse olfactory habituation-dishabituation task, using a single side-view camera, resulting in occluded body parts. We created a pipeline for task analysis, combining DeepLabCut, for pose-estimation, and SimBA, for behavioural classification to automatically quantify odour interaction (sniffing time) in a three-odour (water, familiar mouse social odour, novel mouse social odour) variant of the task. We used a subset of previously published, fully manually annotated datasets to train the models and unseen videos from the same study to validate the utility of our machine learning pipeline. Results and conclusion: Our analysis pipeline estimated behavioural performance in the task with high accuracy, and the data produces similar technical and biological results to manual methods when analysed by linear mixed modelling. Thus, we validated the utility of our new pipeline for the automated scoring of this mouse sensory task.
- Open Access
- 1 August 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (8)
Multi-modal comparative phenotyping of knock-in mouse models of frontotemporal dementia/amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive adult-onset neurodegenerative diseases with overlapping pathological and genetic origins. They are caused by multiple underlying mechanisms leading to a common collection of clinical features that occur in a spectrum. Here, we report side-by-side longitudinal behavioural, cognitive and sensory phenotyping of two mouse models of ALS/FTD, to determine which aspects of the disease they recapitulate. We used knock-in models, in which the endogenous mouse orthologues of the C9orf72 and TARDBP (encoding TDP-43) genes have been altered to model specific molecular aspects of ALS/FTD. We found that the C9orf72GR400/+ model exhibits age-related deficit in short-term memory and that parental genotype affects exploration activity in offspring. In the TardbpQ331K/Q331K model, we found age-related changes in weight, fat mass, locomotion and marble burying. In both models, we found no evidence of deficits in vision or olfactory habituation-dishabituation. These data provide new insight into genotype-phenotype relationships in these ALS/FTD mice, which can be used to inform model choice and experimental design in future research studies.
- 1 August 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (8)
Open AccessMulti-modal comparative phenotyping of knock-in mouse models of frontotemporal dementia/amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive adult-onset neurodegenerative diseases with overlapping pathological and genetic origins. They are caused by multiple underlying mechanisms leading to a common collection of clinical features that occur in a spectrum. Here, we report side-by-side longitudinal behavioural, cognitive and sensory phenotyping of two mouse models of ALS/FTD, to determine which aspects of the disease they recapitulate. We used knock-in models, in which the endogenous mouse orthologues of the C9orf72 and TARDBP (encoding TDP-43) genes have been altered to model specific molecular aspects of ALS/FTD. We found that the C9orf72GR400/+ model exhibits age-related deficit in short-term memory and that parental genotype affects exploration activity in offspring. In the TardbpQ331K/Q331K model, we found age-related changes in weight, fat mass, locomotion and marble burying. In both models, we found no evidence of deficits in vision or olfactory habituation-dishabituation. These data provide new insight into genotype-phenotype relationships in these ALS/FTD mice, which can be used to inform model choice and experimental design in future research studies.
- Open Access
- 19 May 2025
- Published by Springer Nature in Acta Neuropathologica
- Vol. 149 (1) , 1-33
Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome–Alzheimer’s disease (DSAD) to demographically matched cases of early onset AD and healthy ageing controls. We find dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells, and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high risk of early onset dementia.
- 19 May 2025
- Published by Springer Nature in Acta Neuropathologica
- Vol. 149 (1) , 1-33
Open AccessApolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome–Alzheimer’s disease (DSAD) to demographically matched cases of early onset AD and healthy ageing controls. We find dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells, and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high risk of early onset dementia.
- Open Access
Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome-Alzheimer’s disease
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome-Alzheimer’s disease (DSAD) to demographically matched cases of early-onset AD and healthy ageing controls. We find wide dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high-risk of early-onset dementia.
Open AccessApolipoprotein E abundance is elevated in the brains of individuals with Down syndrome-Alzheimer’s disease
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome-Alzheimer’s disease (DSAD) to demographically matched cases of early-onset AD and healthy ageing controls. We find wide dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high-risk of early-onset dementia.